2696 — Shanghai Henlius Biotech Share News
0.000.00%
Last trade - 00:00- HK$35.72bn
- HK$39.39bn
- CNY6.67bn
Brief: Shanghai Henlius Biotech Enters License Agreement With Sandoz For Hlx13
Brief: Shanghai Henlius Biotech Enters License Agreement With Alvogen Korea
Brief: Shanghai Fosun Pharmaceutical's Unit To Buy Stake In Henlius Biotech
Brief: Shanghai Henlius Biotech Updates On Phase 3 Clinical Study Of HLX04-O
Brief: Shanghai Henlius Biotech Updates On Pertuzumab Biosimilar HLX11
Brief: Shanghai Henlius Biotech Updates On Phase 2 Clinical Trial Of HLX79 Injection
Brief: Shanghai Henlius Biotech Says Wenjie Zhang Re-Designated From Executive Director
Brief: Shanghai Henlius Biotech Posts FY Revenue RMB 5,724.4 Million
Brief: Shanghai Henlius Biotech Says Orphan-Drug Designation Granted By US FDA
Brief: UBS Group's Long Position In H Shares Of Shanghai Henlius Biotech Increases To 7.55% - HKEX
Brief: Shanghai Henlius Biotech's New Drug Application Of Innovative Small Molecular Hlx99 Approved By U.S. FDA
Henlius soars on deal with India's Dr. Reddy's Labs for myeloma drug
Brief: Shanghai Henlius Biotech Says License Agreement With Dr. Reddy's For HLX15
Brief: Shanghai Henlius Biotech Says European Commission Approved Serplulimab Injection
Brief: Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Henlius Biotech at 9-month low as shareholders reject buyout offer
Deals of the day-Mergers and acquisitions
Henlius Biotech shareholders reject take-private offer from China's Fosun (updated)
Henlius Biotech shareholders reject take-private offer from China's Fosun